Bexarotene plus Erlotinib Suppresses Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models

The rexinoid bexarotene represses cyclin D1 by causing its proteasomal degradation. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib represses cyclin D1 via different mechanisms. We conducted a preclinical study and two clinical/translational trials (a window-of-...

詳細記述

保存先:
書誌詳細
主要な著者: Dragnev, Konstantin H., Ma, Tian, Cyrus, Jobin, Galimberti, Fabrizio, Memoli, Vincent, Busch, Alexander M., Tsongalis, Gregory J., Seltzer, Marc, Johnstone, David, Erkmen, Cherie P., Nugent, William, Rigas, James R., Liu, Xi, Freemantle, Sarah, Kurie, Jonathan M., Waxman, Samuel, Dmitrovsky, Ethan
フォーマット: Artigo
言語:Inglês
出版事項: 2011
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3108499/
https://ncbi.nlm.nih.gov/pubmed/21636548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-10-0376
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料